Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma

NCT04495257 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04495257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
Lead sponsor
Yale University
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2020
Completion date
March 4, 2026
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, renal cell carcinoma